170289-36-8 Usage
Description
2-(Bromomethyl)-3,5-dimethylpyridine, a pyridine derivative with the molecular formula C8H10BrN, features a bromomethyl group at the 2-position and two methyl groups at the 3and 5-positions. This chemical compound is a clear, colorless liquid with a pungent odor and is known for its flammability. It serves as a versatile intermediate in the synthesis of pharmaceuticals and agrochemicals, as well as a building block in organic synthesis and a reagent in various chemical reactions.
Uses
Used in Pharmaceutical Synthesis:
2-(Bromomethyl)-3,5-dimethylpyridine is utilized as an intermediate in the production of various pharmaceuticals. Its unique structure allows for the creation of new compounds with potential therapeutic properties, contributing to the development of novel medications.
Used in Agrochemical Production:
In the agrochemical industry, 2-(Bromomethyl)-3,5-dimethylpyridine serves as a key intermediate for the synthesis of pesticides and other crop protection agents. Its incorporation into these products can enhance their effectiveness in protecting crops from pests and diseases.
Used in Organic Synthesis:
As a building block in organic synthesis, 2-(Bromomethyl)-3,5-dimethylpyridine is employed in the construction of complex organic molecules. Its presence in these molecules can impart specific chemical properties, making it a valuable component in the synthesis of a wide range of organic compounds.
Used in Chemical Reactions as a Reagent:
2-(Bromomethyl)-3,5-dimethylpyridine also functions as a reagent in various chemical reactions, facilitating the formation of desired products. Its reactivity and structural features make it a useful tool in the synthesis of a variety of chemical compounds.
Safety Precautions:
Due to its flammable nature, 2-(Bromomethyl)-3,5-dimethylpyridine should be handled with care and stored in a cool, well-ventilated area away from sources of ignition to prevent accidents and ensure safe usage in various applications.
Check Digit Verification of cas no
The CAS Registry Mumber 170289-36-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,0,2,8 and 9 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 170289-36:
(8*1)+(7*7)+(6*0)+(5*2)+(4*8)+(3*9)+(2*3)+(1*6)=138
138 % 10 = 8
So 170289-36-8 is a valid CAS Registry Number.
170289-36-8Relevant articles and documents
Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity
Kasibhatla, Srinivas R.,Hong, Kevin,Biamonte, Marco A.,Busch, David J.,Karjian, Patricia L.,Sensintaffar, John L.,Kamal, Adeela,Lough, Rachel E.,Brekken, John,Lundgren, Karen,Grecko, Roy,Timony, Gregg A.,Ran, Yingqing,Mansfield, Robert,Fritz, Lawrence C.,Ulm, Edgar,Burrows, Francis J.,Boehm, Marcus F.
, p. 2767 - 2778 (2008/02/06)
Heat shock protein 90 (Hsp90) is a molecular chaperone protein implicated in stabilizing the conformation and maintaining the function of many cell-signaling proteins. Many oncogenic proteins are more dependent on Hsp90 in maintaining their conformation, stability, and maturation than their normal counterparts. Furthermore, recent data show that Hsp90 exists in an activated form in malignant cells but in a latent inactive form in normal tissues, suggesting that inhibitors selective for the activated form could provide a high therapeutic index. Hence, Hsp90 is emerging as an exciting new target for the treatment of cancer. We now report on a novel series of 2-amino-6-halopurine Hsp90 inhibitors exemplified by 2-amino-6-chloro-9-(4-iodo-3,5-dimethylpyridin- 2-ylmethyl)purine (30). These highly potent inhibitors (IC50 of 30 = 0.009 μM in a HER-2 degradation assay) also display excellent antiproliferative activity against various tumor cell lines (IC50 of 30 = 0.03 μM in MCF7 cells). Moreover, this class of inhibitors shows higher affinity for the activated form of Hsp90 compared to our earlier 8-sulfanylpurine Hsp90 inhibitor series. When administered orally to mice, these compounds exhibited potent tumor growth inhibition (>80%) in an N87 xenograft model, similar to that observed with 17-allylamino-17- desmethoxygeldanamycin (17-AAG), which is a compound currently in phase I/II clinical trials.
